Potencial do vírus da doença de Newcastle para a luta contra o câncer em animais
Palavras-chave:
NDV, câncer animal, viroterapia oncolítica.
Resumo
Este artigo de revisão descreve o uso do vírus da doença de Newcastle (NDV) como agente oncolítico, características biológicas relevantes de diversas cepas oncolíticas, os mecanismos de oncólise, as suas atividades imunológicas e vários aspectos de segurança são considerados no uso do NDV na viroterapia oncolítica (VTO) contra o câncer em seres humanos e animais. O uso deste vírus em estudos clínicos de VTO em animais domésticos e silvestres é fortemente sugerido, sendo uma opção barata, segura e de alta eficácia para o tratamento das neoplasias.
Referências
REFERÊNCIAS BIBLIOGRÁFICAS
1- Boddy AM et al. Comparative oncology: new insights into an ancient disease. iScience, 23, 101373, 2020. https://www.cell.com/action/showPdf?pii=S2589-0042%2820%2930561-7.
2- Hamede R et al. The ecology and evolution of wildlife cancers: applications for management and conservation. Evolutionary Applications, 13:1719–1732, 2020. https://onlinelibrary.wiley.com/doi/epdf/10.1111/eva.12948.
3- Lam HY et al. Safety and clinical usage of Newcastle disease virus in cancer therapy. Journal of Biomedicine and Biotechnology, v. 2011. https://www.hindawi.com/journals/bmri/2011/718710/.
4- Oh JH et al. Comparative oncology: overcoming human cancer through companion animal studies. Experimental & Molecular Medicine, 55:725 – 734, 2023. https://www.nature.com/articles/s12276-023-00977-3.
5- Cekanova M et al. Animal models and therapeutic molecular targets of cancer: utility and limitations. Drug Design, Development and Therapy, 8: 1911–1922, 2014. https://www.dovepress.com/getfile.php?fileID=22022.
6- Schirrmacher V. From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment (Review). International Journal of Oncology, 54: 407-419, 2018. https://www.spandidos-publications.com/10.3892/ijo.2018.4661.
7- Meng Q et al. Advances in the study of antitumour immunotherapy for Newcastle Disease Virus. International Journal of Medical Sciences, 18(11): 2294-2302, 2021. https://www.medsci.org/v18p2294.htm.
8- Patil SS et al. Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients. Journal of Translational Medicine, 10:3, 2012. https://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-10-3.
9- Gentschev I et al. Oncolytic virotherapy of canine and feline cancer. Viruses, 6, 2122-2137, 2014. https://www.mdpi.com/1999-4915/6/5/2122.
10- Macneill AL. On the potential of oncolytic virotherapy for the treatment of canine cancers. Oncolytic Virotherapy, 4:95–107, 2015. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918385/.
11- Bilgiç B et al. Oncolytic virotherapy and the current approaches in veterinary medicine. German Journal of Veterinary Research, 2(2):17-27, 2022. https://gmpc-akademie.de/articles/gjvr/single/68.
12- Kwon JY et al. Canine as a comparative and translational model for human mammary tumor. Journal Breast Cancer, 26(1):1-13, 2023. https://ejbc.kr/DOIx.php?id=10.4048/jbc.2023.26.e4.
13- Sánchez D et al. Oncolytic viruses for canine cancer treatment. Cancers, 10, 404, 2018. https://www.mdpi.com/2072-6694/10/11/404.
14- Melcher A et al. Oncolytic virotherapy as immunotherapy. Science, 374, 1325-1326, 2021. https://www.science.org/doi/10.1126/science.abk3436.
15- Rodrigues L et al. Shared hotspot mutations in oncogenes position dogs as an unparalleled comparative model for precision therapeutics. Nature Scientifc Reports, 13:10935, 2023. https://www.nature.com/articles/s41598-023-37505-2.
16- Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nature Reviews, 8, 147-156, 2008. https://www.nature.com/articles/nrc2273.
17- Lin D et al. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduction and Targeted Therapy, 8:156, 2023. https://www.nature.com/articles/s41392-023-01407-6.
18- Russell L et al. Oncolytic viruses: priming time for cancer immunotherapy. BioDrugs 33:485–501, 2019. https://link.springer.com/article/10.1007/s40259-019-00367-0.
19- Zamarin D, Palese P. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiology, 7(3): 347–367, 2012. https://www.futuremedicine.com/doi/10.2217/fmb.12.4.
20- Burman B et al. Newcastle disease virus at the forefront of cancer immunotherapy. Cancers, 12, 3552, 2020. https://www.mdpi.com/2072-6694/12/12/3552.
21- Schirrmacher V. Molecular mechanisms of anti-neoplastic and immune stimulatory properties of oncolytic Newcastle disease virus. Biomedicines, 10, 562, 2022. https://www.mdpi.com/2227-9059/10/3/562.
22- Ross CS et al. JMM Profile: Avian paramyxovirus type-1 and Newcastle disease: a highly infectious vaccine-preventable viral disease of poultry with low zoonotic potential. Journal of Medical Microbiology, 71:001489, 2022. https://www.microbiologyresearch.org/content/journal/jmm/10.1099/jmm.0.001489.
23- Sánchez D et al. Newcastle disease virus: potential therapeutic application for human and canine lymphoma. Viruses, 8:3 2016. https://www.mdpi.com/1999-4915/8/1/3.
24- Santos MR et al. Oncolytic effect of Newcastle disease virus is attributed to interferon regulation in canine mammary cancer cell lines. Veterinary and Comparative Oncology, 19:593–601, 2021. https://onlinelibrary.wiley.com/doi/10.1111/vco.12699.
25- Sinkovics JG, Horvath JC. Newcastle disease virus (NDV): brief history of its oncolytic strains. Journal of Clinical Virology, 16, 1–15, 2000. https://www.sciencedirect.com/science/article/abs/pii/S1386653299000724?via%3Dihub.
26- Chen L et al. Oncolytic activity of wild-type Newcastle disease virus HK84 against hepatocellular carcinoma associated with activation of type I interferon signaling. Journal of Clinical and Translational Hepatology, 10(2):284–296, 2022. https://www.xiahepublishing.com/2310-8819/JCTH-2021-00284.
27- Ch’ng WC et al. The oncolytic activity of Newcastle disease virus in clear cell renal carcinoma cells in normoxic and hypoxic conditions: the interplay between von Hippel-Lindau and interferon-b signaling. Journal of Interferon & Cytokine Research, 33(7), 2013. https://www.liebertpub.com/doi/10.1089/jir.2012.0095.
28- Jiang K et al. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells. BMC Cancer, 18:746, 2018. https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4522-3.
29- Yurchenko KS et al. Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model. PLoS ONE, 13(4), e0195425, 2018. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0195425.
30- Assayaghi RM et al. Apoptosis induction of Newcastle disease virus strains (AF 2240 & V4-UPM) on HT-29 human colorectal adenocarcinoma cells. Journal of Cancer Research and Therapeutic Oncology, 4:101, 2016. https://www.jscholaronline.org/full-text/JCRTO/5_101/Apoptosis-Induction-of-Newcastle-Disease-Virus-Strains.php.
31- Yurchenko KS et al. Adaptation of the Newcastle disease virus to cell cultures for enhancing its oncolytic properties. Acta Naturae, 11(40), 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475870/.
32- Khansari N, Bonab SF. Virotherapy with Newcastle disease virus for cancer treatment and its efficacy in clinical trials. Journal of Immunology Research, 5(6):119‒122, 2017. https://medcraveonline.com/MOJI/MOJI-05-00176.pdf.
33- Plitt T, Zamarin D. Cancer therapy with Newcastle disease virus: rationale for new immunotherapeutic combinations. Journal of Clinical Investigation, 5(1), 75–87, 2015. https://www.openaccessjournals.com/articles/cancer-therapy-with-newcastle-disease-virus-rationale-for-new-immunotherapeutic-combinations.pdf.
34- Tayeb S et al. Therapeutic potential of oncolytic Newcastle disease virus: a critical review. Oncolytic Virotherapy, 4:2015. https://www.dovepress.com/therapeutic-potential-of-oncolytic-newcastle-disease-virus-a-critical--peer-reviewed-fulltext-article-OV.
35- Fiola C et al. Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. International Journal of Cancer, 119, 328–338, 2006. https://onlinelibrary.wiley.com/doi/10.1002/ijc.21821.
36- Rivera OAO et al. Inhibition of tumor growth and metastasis by Newcastle disease virus strain P05 in a breast cancer mouse model. Journal Breast Cancer, 26(2):186-200, 2023. https://ejbc.kr/DOIx.php?id=10.4048/jbc.2023.26.e9.
37- Ye T et al. Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells. American Journal Cancer Research, 8(8):1514-1527, 2018. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129498/.
38- Cuoco JA et al. The oncolytic Newcastle disease virus as an effective immunotherapeutic strategy against glioblastoma. Neurosurgical Focus, v. 50, 2021. https://thejns.org/focus/view/journals/neurosurg-focus/50/2/article-pE8.xml.
39- Burke S et al. Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro. Cancer Immunology, Immunotherapy, 69:1015–1027, 2020. https://link.springer.com/article/10.1007/s00262-020-02495-x.
40- Ivanković S et al. Oncolytic activity of Newcastle disease virus strain ZG1999HDS on oral malignant melanoma in dog: a case report. Veterinaria, 71(2), 243-254, 2022. https://journal.veterinaria-sarajevo.com/vfs/index.php/journal/article/view/380.
41- Cassel WA, Garrett RE. Newcastle disease virus as an antineoplastic agent. Cancer v. 18, 1965. https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/1097-0142(196507)18:7%3C863::AID-CNCR2820180714%3E3.0.CO;2-V.
42- Pathak U et al. The viral knock: ameliorating cancer treatment with oncolytic Newcastle disease virus. Life,13,1626, 2023. https://doi.org/10.3390/ life13081626. https://www.mdpi.com/2075-1729/13/8/1626.
43- Siswanto FM, Arunngam P. Combination of oncolytic Newcastle disease virus (Ndv) and vaccine vector adenovirus (Adv) as a potential virotherapy for cancer: a systematic review. Anatomy Physiology & Biochemistry International Journal, 4(5): 555649, 2018. https://juniperpublishers.com/apbij/pdf/APBIJ.MS.ID.555649.pdf.
44- Achard C et al. Lighting a fire in the tumor microenvironment using oncolytic immunotherapy. Life, 13, 1626, 2023. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(18)30148-8/fulltext.
45- Alkassar M et al. The combined effects of oncolytic reovirus plus Newcastle disease virus and reovirus plus parvovirus on U87 and U373 cells in vitro and in vivo. Journal of Neuro-Oncology, 104(3):715–727, 2011. https://link.springer.com/article/10.1007/s11060-011-0606-5.
46- Mcausland TM et al. Combining vanadyl sulfate with Newcastle disease virus potentiates rapid innate immune-mediated regression with curative potential in murine cancer models. Molecular Therapy: Oncolytics, 20, 2021.
47- Zhang Y et al. Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy. Cancer Cell International, 21:262, 2021. https://cancerci.biomedcentral.com/articles/10.1186/s12935-021-01972-2.
48- Lovatt C, Parker AL. Oncolytic viruses and immune checkpoint inhibitors: the “hot” new power couple. Cancers, 15, 4178, 2023. https://www.mdpi.com/2072-6694/15/16/4178.
49- Vijayakumar G et al. Engineering Newcastle disease virus as an oncolytic vector for intratumoral delivery of immune checkpoint inhibitors and immunocytokines. Journal of Virology, 94:e01677-19. https://journals.asm.org/doi/10.1128/jvi.01677-19.
50- Schirrmacher V, Fournier P. Multimodal cancer therapy involving oncolytic Newcastle disease virus, autologous immune cells, and bi-specific. Frontiers in Oncology, 4, 224, 2014. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2014.00224/full.
51- Thomas RJ, Bartee E. The use of oncolytic virotherapy in the neoadjuvant setting. Journal for ImmunoTherapy of Cancer, 10:e004462. https://jitc.bmj.com/content/10/4/e004462.
52- Schirrmacher V. Fifty years of clinical application of Newcastle disease virus: time to celebrate! Biomedicines, 4:16, 2016. https://www.mdpi.com/2227-9059/4/3/16.
53- Queiroga F, Cogliati B. Translational and comparative research on innovative anti-cancer therapies. Cancers, 15, 1335, 2023. https://www.mdpi.com/2072-6694/15/4/1335.
54- Biller BJ. Cancer immunotherapy for the veterinary patient. Veterinary Clinics Small Animal, 37:1137–1149, 2007. https://www.sciencedirect.com/science/article/abs/pii/S0195561607000903?via%3Dihub.
1- Boddy AM et al. Comparative oncology: new insights into an ancient disease. iScience, 23, 101373, 2020. https://www.cell.com/action/showPdf?pii=S2589-0042%2820%2930561-7.
2- Hamede R et al. The ecology and evolution of wildlife cancers: applications for management and conservation. Evolutionary Applications, 13:1719–1732, 2020. https://onlinelibrary.wiley.com/doi/epdf/10.1111/eva.12948.
3- Lam HY et al. Safety and clinical usage of Newcastle disease virus in cancer therapy. Journal of Biomedicine and Biotechnology, v. 2011. https://www.hindawi.com/journals/bmri/2011/718710/.
4- Oh JH et al. Comparative oncology: overcoming human cancer through companion animal studies. Experimental & Molecular Medicine, 55:725 – 734, 2023. https://www.nature.com/articles/s12276-023-00977-3.
5- Cekanova M et al. Animal models and therapeutic molecular targets of cancer: utility and limitations. Drug Design, Development and Therapy, 8: 1911–1922, 2014. https://www.dovepress.com/getfile.php?fileID=22022.
6- Schirrmacher V. From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment (Review). International Journal of Oncology, 54: 407-419, 2018. https://www.spandidos-publications.com/10.3892/ijo.2018.4661.
7- Meng Q et al. Advances in the study of antitumour immunotherapy for Newcastle Disease Virus. International Journal of Medical Sciences, 18(11): 2294-2302, 2021. https://www.medsci.org/v18p2294.htm.
8- Patil SS et al. Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients. Journal of Translational Medicine, 10:3, 2012. https://translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-10-3.
9- Gentschev I et al. Oncolytic virotherapy of canine and feline cancer. Viruses, 6, 2122-2137, 2014. https://www.mdpi.com/1999-4915/6/5/2122.
10- Macneill AL. On the potential of oncolytic virotherapy for the treatment of canine cancers. Oncolytic Virotherapy, 4:95–107, 2015. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918385/.
11- Bilgiç B et al. Oncolytic virotherapy and the current approaches in veterinary medicine. German Journal of Veterinary Research, 2(2):17-27, 2022. https://gmpc-akademie.de/articles/gjvr/single/68.
12- Kwon JY et al. Canine as a comparative and translational model for human mammary tumor. Journal Breast Cancer, 26(1):1-13, 2023. https://ejbc.kr/DOIx.php?id=10.4048/jbc.2023.26.e4.
13- Sánchez D et al. Oncolytic viruses for canine cancer treatment. Cancers, 10, 404, 2018. https://www.mdpi.com/2072-6694/10/11/404.
14- Melcher A et al. Oncolytic virotherapy as immunotherapy. Science, 374, 1325-1326, 2021. https://www.science.org/doi/10.1126/science.abk3436.
15- Rodrigues L et al. Shared hotspot mutations in oncogenes position dogs as an unparalleled comparative model for precision therapeutics. Nature Scientifc Reports, 13:10935, 2023. https://www.nature.com/articles/s41598-023-37505-2.
16- Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nature Reviews, 8, 147-156, 2008. https://www.nature.com/articles/nrc2273.
17- Lin D et al. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduction and Targeted Therapy, 8:156, 2023. https://www.nature.com/articles/s41392-023-01407-6.
18- Russell L et al. Oncolytic viruses: priming time for cancer immunotherapy. BioDrugs 33:485–501, 2019. https://link.springer.com/article/10.1007/s40259-019-00367-0.
19- Zamarin D, Palese P. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiology, 7(3): 347–367, 2012. https://www.futuremedicine.com/doi/10.2217/fmb.12.4.
20- Burman B et al. Newcastle disease virus at the forefront of cancer immunotherapy. Cancers, 12, 3552, 2020. https://www.mdpi.com/2072-6694/12/12/3552.
21- Schirrmacher V. Molecular mechanisms of anti-neoplastic and immune stimulatory properties of oncolytic Newcastle disease virus. Biomedicines, 10, 562, 2022. https://www.mdpi.com/2227-9059/10/3/562.
22- Ross CS et al. JMM Profile: Avian paramyxovirus type-1 and Newcastle disease: a highly infectious vaccine-preventable viral disease of poultry with low zoonotic potential. Journal of Medical Microbiology, 71:001489, 2022. https://www.microbiologyresearch.org/content/journal/jmm/10.1099/jmm.0.001489.
23- Sánchez D et al. Newcastle disease virus: potential therapeutic application for human and canine lymphoma. Viruses, 8:3 2016. https://www.mdpi.com/1999-4915/8/1/3.
24- Santos MR et al. Oncolytic effect of Newcastle disease virus is attributed to interferon regulation in canine mammary cancer cell lines. Veterinary and Comparative Oncology, 19:593–601, 2021. https://onlinelibrary.wiley.com/doi/10.1111/vco.12699.
25- Sinkovics JG, Horvath JC. Newcastle disease virus (NDV): brief history of its oncolytic strains. Journal of Clinical Virology, 16, 1–15, 2000. https://www.sciencedirect.com/science/article/abs/pii/S1386653299000724?via%3Dihub.
26- Chen L et al. Oncolytic activity of wild-type Newcastle disease virus HK84 against hepatocellular carcinoma associated with activation of type I interferon signaling. Journal of Clinical and Translational Hepatology, 10(2):284–296, 2022. https://www.xiahepublishing.com/2310-8819/JCTH-2021-00284.
27- Ch’ng WC et al. The oncolytic activity of Newcastle disease virus in clear cell renal carcinoma cells in normoxic and hypoxic conditions: the interplay between von Hippel-Lindau and interferon-b signaling. Journal of Interferon & Cytokine Research, 33(7), 2013. https://www.liebertpub.com/doi/10.1089/jir.2012.0095.
28- Jiang K et al. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells. BMC Cancer, 18:746, 2018. https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4522-3.
29- Yurchenko KS et al. Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model. PLoS ONE, 13(4), e0195425, 2018. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0195425.
30- Assayaghi RM et al. Apoptosis induction of Newcastle disease virus strains (AF 2240 & V4-UPM) on HT-29 human colorectal adenocarcinoma cells. Journal of Cancer Research and Therapeutic Oncology, 4:101, 2016. https://www.jscholaronline.org/full-text/JCRTO/5_101/Apoptosis-Induction-of-Newcastle-Disease-Virus-Strains.php.
31- Yurchenko KS et al. Adaptation of the Newcastle disease virus to cell cultures for enhancing its oncolytic properties. Acta Naturae, 11(40), 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475870/.
32- Khansari N, Bonab SF. Virotherapy with Newcastle disease virus for cancer treatment and its efficacy in clinical trials. Journal of Immunology Research, 5(6):119‒122, 2017. https://medcraveonline.com/MOJI/MOJI-05-00176.pdf.
33- Plitt T, Zamarin D. Cancer therapy with Newcastle disease virus: rationale for new immunotherapeutic combinations. Journal of Clinical Investigation, 5(1), 75–87, 2015. https://www.openaccessjournals.com/articles/cancer-therapy-with-newcastle-disease-virus-rationale-for-new-immunotherapeutic-combinations.pdf.
34- Tayeb S et al. Therapeutic potential of oncolytic Newcastle disease virus: a critical review. Oncolytic Virotherapy, 4:2015. https://www.dovepress.com/therapeutic-potential-of-oncolytic-newcastle-disease-virus-a-critical--peer-reviewed-fulltext-article-OV.
35- Fiola C et al. Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. International Journal of Cancer, 119, 328–338, 2006. https://onlinelibrary.wiley.com/doi/10.1002/ijc.21821.
36- Rivera OAO et al. Inhibition of tumor growth and metastasis by Newcastle disease virus strain P05 in a breast cancer mouse model. Journal Breast Cancer, 26(2):186-200, 2023. https://ejbc.kr/DOIx.php?id=10.4048/jbc.2023.26.e9.
37- Ye T et al. Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells. American Journal Cancer Research, 8(8):1514-1527, 2018. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6129498/.
38- Cuoco JA et al. The oncolytic Newcastle disease virus as an effective immunotherapeutic strategy against glioblastoma. Neurosurgical Focus, v. 50, 2021. https://thejns.org/focus/view/journals/neurosurg-focus/50/2/article-pE8.xml.
39- Burke S et al. Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro. Cancer Immunology, Immunotherapy, 69:1015–1027, 2020. https://link.springer.com/article/10.1007/s00262-020-02495-x.
40- Ivanković S et al. Oncolytic activity of Newcastle disease virus strain ZG1999HDS on oral malignant melanoma in dog: a case report. Veterinaria, 71(2), 243-254, 2022. https://journal.veterinaria-sarajevo.com/vfs/index.php/journal/article/view/380.
41- Cassel WA, Garrett RE. Newcastle disease virus as an antineoplastic agent. Cancer v. 18, 1965. https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/1097-0142(196507)18:7%3C863::AID-CNCR2820180714%3E3.0.CO;2-V.
42- Pathak U et al. The viral knock: ameliorating cancer treatment with oncolytic Newcastle disease virus. Life,13,1626, 2023. https://doi.org/10.3390/ life13081626. https://www.mdpi.com/2075-1729/13/8/1626.
43- Siswanto FM, Arunngam P. Combination of oncolytic Newcastle disease virus (Ndv) and vaccine vector adenovirus (Adv) as a potential virotherapy for cancer: a systematic review. Anatomy Physiology & Biochemistry International Journal, 4(5): 555649, 2018. https://juniperpublishers.com/apbij/pdf/APBIJ.MS.ID.555649.pdf.
44- Achard C et al. Lighting a fire in the tumor microenvironment using oncolytic immunotherapy. Life, 13, 1626, 2023. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(18)30148-8/fulltext.
45- Alkassar M et al. The combined effects of oncolytic reovirus plus Newcastle disease virus and reovirus plus parvovirus on U87 and U373 cells in vitro and in vivo. Journal of Neuro-Oncology, 104(3):715–727, 2011. https://link.springer.com/article/10.1007/s11060-011-0606-5.
46- Mcausland TM et al. Combining vanadyl sulfate with Newcastle disease virus potentiates rapid innate immune-mediated regression with curative potential in murine cancer models. Molecular Therapy: Oncolytics, 20, 2021.
47- Zhang Y et al. Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy. Cancer Cell International, 21:262, 2021. https://cancerci.biomedcentral.com/articles/10.1186/s12935-021-01972-2.
48- Lovatt C, Parker AL. Oncolytic viruses and immune checkpoint inhibitors: the “hot” new power couple. Cancers, 15, 4178, 2023. https://www.mdpi.com/2072-6694/15/16/4178.
49- Vijayakumar G et al. Engineering Newcastle disease virus as an oncolytic vector for intratumoral delivery of immune checkpoint inhibitors and immunocytokines. Journal of Virology, 94:e01677-19. https://journals.asm.org/doi/10.1128/jvi.01677-19.
50- Schirrmacher V, Fournier P. Multimodal cancer therapy involving oncolytic Newcastle disease virus, autologous immune cells, and bi-specific. Frontiers in Oncology, 4, 224, 2014. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2014.00224/full.
51- Thomas RJ, Bartee E. The use of oncolytic virotherapy in the neoadjuvant setting. Journal for ImmunoTherapy of Cancer, 10:e004462. https://jitc.bmj.com/content/10/4/e004462.
52- Schirrmacher V. Fifty years of clinical application of Newcastle disease virus: time to celebrate! Biomedicines, 4:16, 2016. https://www.mdpi.com/2227-9059/4/3/16.
53- Queiroga F, Cogliati B. Translational and comparative research on innovative anti-cancer therapies. Cancers, 15, 1335, 2023. https://www.mdpi.com/2072-6694/15/4/1335.
54- Biller BJ. Cancer immunotherapy for the veterinary patient. Veterinary Clinics Small Animal, 37:1137–1149, 2007. https://www.sciencedirect.com/science/article/abs/pii/S0195561607000903?via%3Dihub.
Publicado
2023-12-20
Seção
Saúde
Declaro que os conteúdos apresentados nos artigos e demais trabalhos são de minha autoria e tenho total responsabilidade sobre os mesmos, os quais estou cedendo os direitos autorais à Revista Saúde e Meio Ambiente, para fins de divulgação científica em qualquer meio disponível.
